Vanda Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported beneficial ownership of 5.82% of Vanda Pharmaceuticals Inc. common stock as of June 30, 2026.
NASDAQ
State Street Corporation has reported beneficial ownership of 5.1% of Vanda Pharmaceuticals Inc. common stock as of March 31, 2026.
NASDAQ
BlackRock Portfolio Management LLC has filed a Schedule 13G, reporting beneficial ownership of 4.2% of Vanda Pharmaceuticals Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Vanda Pharmaceuticals Inc. following an internal realignment.
NASDAQ
BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 5.5% beneficial ownership stake in Vanda Pharmaceuticals Inc. common stock.
NASDAQ
Millennium Management LLC and affiliates reported a 2.8% beneficial ownership stake in Vanda Pharmaceuticals Inc. as of December 31, 2025.
NASDAQ
Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a beneficial ownership of 5.3% in Vanda Pharmaceuticals Inc., totaling 3,120,339 shares of common stock.
NASDAQ
BlackRock Portfolio Management LLC has filed a Schedule 13G, reporting a 7.7% beneficial ownership stake in Vanda Pharmaceuticals Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Stake in Vanda Pharmaceuticals to 8.1%
BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Vanda Pharmaceuticals Inc.'s common stock as of January 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 15.6% Passive Stake in Vanda Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 15.6% beneficial ownership stake in Vanda Pharmaceuticals Inc. as of December 31, 2024.